IFNA2 and neoplasm: The emergence of the tumor stroma as a complex and integral part of the tumor mass resulted in the mid-1980s in the approval of treatments based on targeting the tumor stroma (e.g., 1986 IFNA2 treatment), including today’s immunotherapies.